Dr. Jose Galarza (DVM, PhD) is the President and Founder of TechnoVax. Dr. Galarza has more than 30 years of scientific experience in the field of virology and vaccine development and is currently also an adjunct Associate Professor of Microbiology and Immunology at New York Medical College.
Before founding TechnoVax, he was Principal Scientist and leader of the influenza subunit vaccine development program in the Vaccines Division of Wyeth Pharmaceuticals in Pearl River, New York. While at Wyeth, Dr. Galarza and his team invented the “Influenza Virus-Like Particle” technology.
Prior to joining Wyeth Vaccines, Dr. Galarza held research positions at the University of California at Irvine, and the University of Utah Medical Center in Salt Lake City.
Dr. Galarza received a Doctorate in Veterinary Medicine and a Doctorate in Microbiology from the University of La Plata in Argentina. He did is Post-Doc at the University of Utah Medical Center in Salt Lake City in Virology and Molecular Biology.
Dr. George Martin (PhD) is the Chief Technical Officer and co-founder of TechnoVax. He is Scientist Emeritus at the National Institutes of Health and former Senior Vice President for Scientific Affairs of Fibrogen, Inc. in San Francisco.
Dr. Martin has been extensively honored and recognized for his scientific accomplishments and has published more than 350 research papers.
Mr. Hector Munoz (MBA) is the Chief Financial and Corporate Development Officer of TechnoVax. He brings over 20 years of domestic and international corporate experience. Mr. Munoz has held senior management positions in Business Development, Corporate M&A and Trade Marketing with R.J. Reynolds Int’l and with JT Int’l, during which time he has orchestrated multi- million dollar corporate M&A projects, ranging from divestitures to international joint-ventures. Mr. Munoz also possesses extensive financial and commercial experience working in five languages.